Cluster-Randomized Trial of Air Filtration and Ventilation to Reduce Covid19 Spread in Homes

Not Applicable

• Conditions: Covid19

• Registration Number: NCT05777720
• Lead Sponsor: Stanford University

Brief Summary

Investigators are evaluating whether an intervention consisting of box-fans with MERV 16 filters ("filtration fans") and recommendations for improving ventilation in the home can reduce secondary spread of Covid19 from an index case to susceptible contacts within the home.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-01-30
• Study First Submitted: 2023-03-18
• Study First Submitted QC: 2023-03-18
• Study First Posted: 2023-03-21
• Status Verified: 2025-06
• Last Update Submitted: 2025-06-11
• Last Update Posted: 2025-06-15
• Primary Completion: 2025-12-30
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Household members live in a shared space (apartment, home) with others (as opposed to renting single rooms in a shared space, for example)
• At least 3 other people live in the household aside from index case

Exclusion Criteria

• If index case test positive day was over 2 days prior
• If half or more household members are thought to be infected already
• If household has fewer than 3 contacts interested in participating in the study
• If fewer than 3 contacts are expected to be present in the house for a majority of the following 7 days

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Incidence of Covid19	7th day since enrollment in the trial	Investigators will measure the incidence of Covid19 in susceptible contacts on day 7.

Secondary Outcome Measures

Name	Time	Method
Average CO2 levels	7 days	Investigators will measure 7 day average CO2 levels in the home (measured in parts per million)
Incidence of new upper respiratory symptoms	7th day since enrollment in the trial	Investigators will measure reported new upper respiratory symptoms in susceptible contacts.

Trial Locations

Locations (2)

San Mateo Medical Center; 🇺🇸 San Mateo, California, United States

Stanford University Medical Center; 🇺🇸 Stanford, California, United States